COVID Treatment that Missed Its Target.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Abstract:
      For example, Rhode Island and Louisiana administered mAbs to the highest proportion of non-hospitalized patients with COVID-19 (24.9% and 21.2%), while Alaska and Washington administered the lowest proportion (1.1% and 0.7%). People over age 65 at the highest risk for severe COVID-19 often have been the least likely to receive monoclonal antibodies (mAbs), a highly effective treatment for the disease, according to research coauthored by researchers from the Harvard School of Public Health. "Monoclonal antibodies should first go to patients at the highest risk of death from COVID-19, but the opposite happened; the healthiest patients were the most likely to get treatment. [Extracted from the article]
    • Abstract:
      Copyright of USA Today Magazine is the property of Society for the Advancement of Education and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)